Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

SEP 28, 2013 - Benzinga

A Must Read - Share

Amgen Reports Phase 3 Trial Comparing Vectibix to Erbitux Meets Primary Endpoint Of Non-Inferiority Of Overall Survival

Amgen (NASDAQ: AMGN) today announced detailed results from the Phase 3 ASPECCT ('763) trial comparing Vectibix® (panitumumab) to Erbitux® (cetuximab) for the treatment of wild-type KRAS metastatic colorectal cancer in patients who have not responded to chemotherapy.

Tags: Amgen Reports Phase 3 Trial Comparing Vectibix to Erbitux Meets Primary Endpoint Of Non-Inferiority Of Overall Survival ,  Amgen Latest News